Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Cosentyx (secukinumab) Disease area(s): Immunology Manufacturer(s): Novartis 2024 Sales (USD): $6.14 billion Why it sold so well: In 2024, Novartis Cosentyx registered significant sales growth, with revenues increasing by 23% year-over-year to $6.14 billion
Dose-Response: Is there a "sweet spot" dose that maximizes weight loss while minimizing dysesthesia
For instance, there have been deaths associated with coffee enemas reported in the U.S.during the 80s
upon binding to TGF1, it recruits TGFBR1 and induces its phosphorylation, thereby activating downstream canonical (SMAD-dependent) and non-canonical (non-SMAD-dependent) intracellular signaling cascades
US$ 23.50
US$ 28.88
US$ 29.54
US$ 20.86
